Zelluna ASA Logo

Zelluna ASA

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Zelluna ASA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 1.0 MB
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 801.4 KB
2025-08-20 07:00
Earnings Release
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 5.6 KB
2025-08-14 12:00
Report Publication Announcement
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
English 1.7 KB
2025-07-03 12:07
Share Issue/Capital Change
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
English 3.4 KB
2025-06-25 16:19
Major Shareholding Notification
Disclosure of share transfer from Inven2 AS
English 711 bytes
2025-05-27 13:51
Major Shareholding Notification
Disclosure of Shareholding - Gjelsten Holding AS
English 1.2 KB
2025-05-27 13:38
Share Issue/Capital Change
ZLNA - New registered share capital
English 1.9 KB
2025-05-24 06:37
Share Issue/Capital Change
ZLNA - Issuance of shares through set-off of option exercise fee
English 2.3 KB
2025-05-08 05:00
Investor Presentation
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 1.3 MB
2025-05-08 05:00
Quarterly Report
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 664.4 KB
2025-05-08 05:00
Earnings Release
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 6.5 KB
2025-04-30 06:00
Report Publication Announcement
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
English 1.7 KB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 4.6 MB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
English 1.4 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nxera Pharma Co., Ltd. Logo Japan 4565
ObsEva SA Logo
Developed therapeutics for women's reproductive health and pregnancy; now winding down operations.
Switzerland OBSN
ODI Pharma AB Logo
Produces and distributes pharmaceutical-grade medicinal cannabis products across Europe.
Sweden ODI
Oncolys BioPharma Inc. Logo Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
OncoTherapy Science, Inc. Logo Japan 4564
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
Orexo Logo
Develops pharmaceuticals for opioid use disorder and pain using innovative drug delivery technology.
Sweden ORX